ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019
Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Global prevalence of macrolide-resistantFrontiers in microbiology · 2025Pooled it
- Infectious Spondylitis Caused by Staphylococcus lugdunensis Following an L-PEN Procedure: A Case Report.Cureus · 2026Article
- Methicillin-resistantFrontiers in medicine · 2026Article
- Article
- Clinical Significance and Microbiological Characteristics ofJournal of clinical medicine · 2024Article
- Article
- Article
- Article
- Manuka honey as a non-antibiotic alternative againstFrontiers in cellular and infection microbiology · 2024Review
- Article
- Searching for Virulence Factors amongInternational journal of molecular sciences · 2023Article
- From Obscurity To Spotlight: Staphylococcus lugdunensis-Induced Infective Endocarditis, a Profound Case Unraveling.Cureus · 2023Article
- Characteristics and outcomes in adult patients with Staphylococcus lugdunensis bacteremia compared to patients with Staphylococcus epidermidis and Staphylococcus aureus bacteremia: a retrospective study in a 16-year period at the university hospital, Japan.BMC infectious diseases · 2023Article
- Trends in coagulase-negative staphylococci (CoNS), England, 2010-2021.Access microbiology · 2023Article
- Staphylococcus lugdunensis Endophthalmitis Following Intravitreal Anti-vascular Endothelial Growth Factor Injections.Cureus · 2022Article
- Article
- AnAntimicrobial agents and chemotherapy · 2022Article
- Antimicrobial Resistance and Antimicrobial Activity ofMicroorganisms · 2022Article
- May Staphylococcus lugdunensis Be an Etiological Factor of Chronic Maxillary Sinuses Infection?International journal of molecular sciences · 2022Article
- Antimicrobial Susceptibility Testing for Staphylococcus lugdunensis.Journal of clinical microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus lugdunensis is a coagulase-negative staphylococcus (CoNS) with unusual pathogenicity resembling that of S. aureus. Unlike other CoNS, S. lugdunensis remains susceptible to most antibiotics. The resistance to penicillin varies widely (range, 15-87% worldwide), whereas methicillin resistance is still rare. We aimed to evaluate treatment options for infections caused by S. lugdunensis and more specifically to investigate whether penicillin G could be a better treatment choice than oxacillin. Susceptibility testing was performed using the disc diffusion method for penicillin G, cefoxitin, trimethoprim/sulfamethoxazole, erythromycin, clindamycin, gentamicin, norfloxacin, fusidic acid, rifampicin, and fosfomycin. Isolates susceptible to penicillin G were further tested with a gradient test for penicillin G and oxacillin. Of the 540 clinical isolates tested, 74.6% were susceptible to penicillin G. Among these penicillin-susceptible isolates, the MIC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.